Accession Number PB2013-103098
Title ACEIs, ARBs, or DRI for Adults with Hypertension. Clinician Research Summary.
Publication Date Oct 2011
Media Count 2p
Personal Author N/A
Abstract Among the many medications for antihypertensive therapy are those aimed at inhibiting or blocking the renin-angiotensin system (RAS). A systematic review of 110 clinical studies published between 1988 and 2010 sought to determine the comparative effectiveness, benefits, and adverse effects of angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II receptor blockers (ARBs), and a direct renin inhibitor (DRI) for adults with hypertension. The report does not review studies comparing: individual drugs within each class, evidence about using these drugs for congestive heart failure or diabetic kidney disease, switching from one drug class to another, or combination therapy. This summary is provided to assist in decisionmaking along with a patients values and preferences. Reviews of evidence should not be construed to represent clinical recommendations or guidelines.
Keywords Adults
Angiotensin II Receptor Blockers(ARBs)
Angiotensin-Converting Enzyme Inhibitors(ACEIs)
Clinical studies
Clinicians
Direct Renin Inhibitor(DRI)
Hypertension
Inhibitors
Medications
Morbidity
Patients
Renin-Angiotensin System(RAS)
Therapy
Product Source: AHRQ

 
Source Agency National Center for Health Services Research
NTIS Subject Category 57E - Clinical Medicine
57F - Cytology, Genetics, & Molecular Biology
57B - Biochemistry
Corporate Author Duke Univ., Durham, NC. Duke Evidence-based Practice Center.
Document Type Technical report
Title Note N/A
NTIS Issue Number 1308
Contract Number AHRQ-290-02-0025

Science and Technology Highlights

See a sampling of the latest scientific, technical and engineering information from NTIS in the NTIS Technical Reports Newsletter

Acrobat Reader Mobile    Acrobat Reader